"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...

Cytokinetics announced the FDA approval of aficamten to improve functional capacity and symptoms in adults with symptomatic ...

A collaboration of researchers in Switzerland, Germany, and the US tracked cardiac function in recreational marathon runners ...

Echocardiograms reveal a rapid rise in LV hypertrophy from ages 17 to 24 years, bolstering the case for primordial prevention.

A new study published in the Journal of American Medical Association showed that reduced right ventricular ejection fraction ...

Valvular heart disease, identified through cardiovascular imaging, is common in cancer patients. Interventions to treat ...

From a global regulatory perspective, Cytokinetics is expanding its footprint rapidly. The drug received approval in China on ...

Severe valvular heart disease (VHD) is prevalent among patients with cancer and is associated with reduced survival, ...

A newly concluded long-term study has reported that children whose parents have poor cardiometabolic health are more likely ...

Valvular heart disease, identified through cardiovascular imaging, is common in cancer patients. Interventions to treat ...